1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Joint Pain - Pipeline Review, H1 2013

Joint Pain - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 25 pages

Joint Pain - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Joint Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Joint Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Joint Pain. Joint Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Joint Pain.
- A review of the Joint Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Joint Pain pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Joint Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Joint Pain pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Joint Pain - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Joint Pain Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Joint Pain 6
Joint Pain Therapeutics under Development by Companies 8
Late Stage Products 9
Comparative Analysis 9
Early Clinical Stage Products 10
Comparative Analysis 10
Joint Pain Therapeutics - Products under Development by Companies 11
Companies Involved in Joint Pain Therapeutics Development 12
Viromed Co., Ltd. 12
Joint Pain - Therapeutics Assessment 13
Assessment by Monotherapy Products 13
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Drug Profiles 18
PG-201 - Drug Profile 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
leconotide - Drug Profile 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Joint Pain Therapeutics - Discontinued Products 20
Joint Pain Therapeutics - Dormant Products 21
Joint Pain - Product Development Milestones 22
Featured News and Press Releases 22
Sep 19, 2012: Imprimis Pharma To Begin New Study Of Topical Analgesic Drug 22
Jul 24, 2006: TissueGene Initiates Phase I Clinical Trial With TG-C 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Tables


Number of Products Under Development for Joint Pain, H1 2013 6
Products under Development for Joint Pain - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Comparative Analysis by Late Stage Development, H1 2013 9
Comparative Analysis by Early Clinical Stage Development, H1 2013 10
Products under Development by Companies, H1 2013 11
Viromed Co., Ltd., H1 2013 12
Assessment by Monotherapy Products, H1 2013 13
Assessment by Stage and Route of Administration, H1 2013 15
Assessment by Stage and Molecule Type, H1 2013 17
Joint Pain Therapeutics - Discontinued Products 20
Joint Pain Therapeutics - Dormant Products 21

List of Figures


Number of Products under Development for Joint Pain, H1 2013 6
Products under Development for Joint Pain - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Late Stage Products, H1 2013 9
Early Clinical Stage Products, H1 2013 10
Assessment by Monotherapy Products, H1 2013 13
Assessment by Route of Administration, H1 2013 14
Assessment by Stage and Route of Administration, H1 2013 15
Assessment by Molecule Type, H1 2013 16
Assessment by Stage and Molecule Type, H1 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2016

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Recepto ...

Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016

Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016’, provides in depth analysis on Cathepsin ...

Peripheral Neuropathic Pain - Pipeline Review, H2 2016

Peripheral Neuropathic Pain - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • October 2016
  • by Global Markets Direct

Peripheral Neuropathic Pain - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Neuropathic Pain - Pipeline Review, H2 2016, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.